Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | Leukemia immune evasion in relapse after haploidentical hematopoietic cell transplantation

Pier Edoardo Rovatti • 1 Sep 2020
EBMT 2020
Acute Myeloid Leukemia Leukemia

Pier Edoardo Rovatti, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Pier Edoardo Rovatti

CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss 7:59
CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss
Pier Edoardo Rovatti • 1 Sep 2020
CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss 7:59
CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss
Pier Edoardo Rovatti • 1 Sep 2020

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals